MBX Biosciences, Inc. Common Stock (MBX) Revenue History
Annual and quarterly revenue from 2022 to present
MBX Revenue Over Time (2022–2025)
MBX Revenue Growth History
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
MBX Revenue Analysis (2022–2025)
Current Revenue & Growth
As of June 28, 2026, MBX Biosciences, Inc. Common Stock (MBX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
MBX's historical revenue data shows various trends over time.
Peer Comparison
Compared to Healthcare sector peers — including KYMR (-12.6% YoY), CYCN (-4.2% YoY), and HALO (+39.1% YoY). Compare MBX vs KYMR →
MBX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MBXCurrent | $0 | - | - | - | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 CYCN | $2M | -4.2% | -2.0% | -239.8% | |
 HALO | $1.4B | +39.1% | +39.2% | 58.4% |
MBX Historical Revenue Data (2022–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-248,000 | - | $-98,055,000 | - |
| 2024 | $0 | - | $0 | - | $-68,194,000 | - |
| 2023 | $0 | - | $0 | - | $-35,311,000 | - |
| 2022 | $0 | - | $0 | - | $-25,161,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MBX — Frequently Asked Questions
Quick answers to the most common questions about buying MBX stock.
Is MBX's revenue growth accelerating or slowing?
MBX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is MBX's revenue history from 2022 to 2026?
MBX Biosciences, Inc. Common Stock (MBX) revenue history spans 2022 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is MBX's long-term revenue growth rate (CAGR)?
MBX Biosciences, Inc. Common Stock's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for MBX.
Why does MBX's quarterly revenue fluctuate?
MBX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. MBX Biosciences, Inc. Common Stock's revenue data from 2022 to 2026 shows full historical quarterly detail on this page.
How is MBX's revenue distributed by segment?
MBX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does MBX's revenue compare to industry peers?
MBX Biosciences, Inc. Common Stock (MBX) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.